Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

NEXT STORY
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted for Virtual Poster Presentation at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
PREV STORY
Gait Rehabilitation System Market Size to Outstrip $451.11Mn by 2028 Growth Projections at 5.8% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

VBL Therapeutics to Report Third Quarter 2017 Results on November 14

TEL AVIV, Israel, Nov. 07, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage ...

author_avatar
NASDAQ Market News

Immunovaccine Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL

HALIFAX, Nova Scotia, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a ...

author_avatar
NASDAQ Market News

ADMA Biologics to Present at Upcoming Investor Conferences

RAMSEY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage ...

author_avatar
NASDAQ Market News